Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer MESHD - a multi-centre North London experience

    Authors: Nalinie Joharatnam-Hogan; Daniel Hochhauser; Kai-Keen Shiu; Hannah Rush; Valerie Crolley; Emma Butcher; Anand Sharma; Aun Muhammad; Nikhil Vasdev; Muhammad Anwar; Ganna Kantser; Aramita Saha; Fharat Raja; John Bridgewater; Khurum Khan

    doi:10.1101/2020.04.16.20061127 Date: 2020-04-17 Source: medRxiv

    Background Four months after the first known case of the 2019 novel coronavirus disease MESHD (COVID-19), on the 11th March 2020, the WHO declared the outbreak a pandemic and acknowledged the potential to overwhelm national healthcare systems. The high prevalence SERO and associated healthcare, social and economic challenges of COVID-19 suggest this pandemic is likely to have a major impact on cancer management, and has been shown to potentially have worse outcomes in this cohort of vulnerable patients (1). This study aims to compare the outcomes of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed COVID-19 positive disease in patients with or without a history of cancer MESHD. Method: We retrospectively collected clinical, pathological and radiological characteristics and outcomes of COVID-19 RT-PCR positive cancer MESHD patients treated consecutively in four different North London hospitals (cohort A). Outcomes recorded included morbidity, mortality and length of hospital stay. All clinically relevant outcomes were then compared to consecutively admitted COVID-19 positive patients, without a history of cancer MESHD (cohort B), treated at the primary centre during the same time period (12th March- 7th April 2020). Results: A total of 52 electronic patient records during the study time period were reviewed. Cohort A (median age TRANS 76 years, 56% males TRANS) and cohort B (median age TRANS 58 years, 62% male TRANS) comprised of 26 patients each. With the exclusion of cancer MESHD, both had a median of 2 comorbidities. Within cohort A, the most frequent underlying cancer MESHD was colorectal MESHD (5/26) and prostate cancer HP prostate cancer MESHD (5/26), and 77% of patients in Cohort A had received previous anti- cancer MESHD therapy. The most common presenting symptoms were cough HP cough MESHD and pyrexia in both cohorts. Frequent laboratory findings included lymphopenia HP lymphopenia MESHD, anaemia MESHD and elevated CRP in both cohorts, whilst hypokalaemia, hypoalbuminaemia and hypoproteinaemia was predominantly seen amongst patients with cancer MESHD. Median duration of admission was 7 days in both cohorts. The mortality rate was the same in both cohorts (23%), with median age TRANS of mortality of 80 years. Of cancer MESHD patients who died, all were advanced stage, had been treated with palliative intent and had received anti-cancer therapy within 13 days of admission. Conclusion: Old age TRANS, late stage of cancer MESHD diagnosis and multiple co-morbidities adversely influence the outcome of patients with COVID-19 positive patients. Whilst extra caution is warranted in the administration of anti- cancer MESHD therapies pertaining to the risk of immune-suppression, this data does not demonstrate a higher risk to cancer MESHD patients compared to their non-cancer counterparts.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.